MIRA MIRA PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1904286
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY100.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-135.7%
ROA-131.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.9%
Debt / equity0.00x
Current ratio16.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-66.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $1.72M | $3.31M | $1.57M | $2.35M |
| SG&A expense | $8.77M | $4.71M | $6.50M | $2.99M |
| Interest expense | — | -$165,669 | $3.46M | $10,250 |
| Net income | -$10.44M | -$7.85M | -$11.98M | -$7.06M |
| EPS (basic) | -1.35 | -0.51 | -0.85 | -0.40 |
| EPS (diluted) | -1.35 | -0.51 | -0.85 | -0.40 |
| Weighted avg. shares (diluted) | — | 15.44M | 13.92M | 17.57M |
| Banking | ||||
| Net interest income | $98,911 | $165,669 | — | — |
| Balance sheet | ||||
| Cash & equivalents | $6.35M | $2.83M | $4.60M | $350,978 |
| Short-term investments | $4.68M | — | — | — |
| Current assets | $11.06M | $2.89M | $4.86M | $494,405 |
| Total assets | $11.09M | $2.92M | $4.93M | $858,074 |
| Current liabilities | $702,068 | $723,349 | $558,097 | $1.37M |
| Total liabilities | $702,068 | $723,349 | $558,097 | $1.45M |
| Shareholders' equity | $10.39M | $2.20M | $4.37M | -$596,232 |
| Shares outstanding | 41.94M | 16.56M | 14.78M | 13.31M |
| Cash flow statement | ||||
| Operating cash flow | -$4.66M | -$5.56M | -$4.53M | -$5.60M |
| Financing cash flow | $8.18M | $3.79M | $8.78M | $3.15M |
| Stock-based compensation | $6.31M | $1.92M | $2.55M | $1.30M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.